ID   MRE11_HUMAN             Reviewed;         708 AA.
AC   P49959; B3KTC7; O43475;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   26-SEP-2001, sequence version 3.
DT   22-JUL-2015, entry version 167.
DE   RecName: Full=Double-strand break repair protein MRE11A;
DE   AltName: Full=Meiotic recombination 11 homolog 1;
DE            Short=MRE11 homolog 1;
DE   AltName: Full=Meiotic recombination 11 homolog A;
DE            Short=MRE11 homolog A;
GN   Name=MRE11A; Synonyms=HNGS1, MRE11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8530104; DOI=10.1006/geno.1995.1217;
RA   Petrini J.H.J., Walsh M.E., Dimare C., Chen X.-N., Korenberg J.R.,
RA   Weaver D.T.;
RT   "Isolation and characterization of the human MRE11 homologue.";
RL   Genomics 29:80-86(1995).
RN   [2]
RP   SEQUENCE REVISION TO C-TERMINUS.
RA   Petrini J.H.J., Walsh M.E., Dimare C., Chen X.-N., Korenberg J.R.,
RA   Weaver D.T.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Chamankhah M., Wei Y., Xiao W.;
RT   "Molecular cloning and functional characterization of hNGS1, a yeast
RT   and human MRE11 homolog.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9651580; DOI=10.1016/S1097-2765(00)80097-0;
RA   Paull T.T., Gellert M.;
RT   "The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA
RT   double-strand breaks.";
RL   Mol. Cell 1:969-979(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=11371508; DOI=10.1093/hmg/10.11.1155;
RA   Pitts S.A., Kullar H.S., Stankovic T., Stewart G.S., Last J.I.K.,
RA   Bedenham T., Armstrong S.J., Piane M., Chessa L., Taylor A.M.R.,
RA   Byrd P.J.;
RT   "hMRE11: genomic structure and a null mutation identified in a
RT   transcript protected from nonsense-mediated mRNA decay.";
RL   Hum. Mol. Genet. 10:1155-1162(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-468 AND VAL-698.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15456891; DOI=10.1128/MCB.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in
RT   the G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [11]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15723659; DOI=10.1111/j.1349-7006.2005.00019.x;
RA   Chen L., Morio T., Minegishi Y., Nakada S., Nagasawa M., Komatsu K.,
RA   Chessa L., Villa A., Lecis D., Delia D., Mizutani S.;
RT   "Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in
RT   response to DNA damage.";
RL   Cancer Sci. 96:134-141(2005).
RN   [12]
RP   INTERACTION WITH ATF2, AND SUBCELLULAR LOCATION.
RX   PubMed=15916964; DOI=10.1016/j.molcel.2005.04.015;
RA   Bhoumik A., Takahashi S., Breitweiser W., Shiloh Y., Jones N.,
RA   Ronai Z.;
RT   "ATM-dependent phosphorylation of ATF2 is required for the DNA damage
RT   response.";
RL   Mol. Cell 18:577-587(2005).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   INTERACTION WITH DCLRE1B.
RX   PubMed=18469862; DOI=10.1038/onc.2008.139;
RA   Bae J.B., Mukhopadhyay S.S., Liu L., Zhang N., Tan J., Akhter S.,
RA   Liu X., Shen X., Li L., Legerski R.J.;
RT   "Snm1B/Apollo mediates replication fork collapse and S Phase
RT   checkpoint activation in response to DNA interstrand cross-links.";
RL   Oncogene 27:5045-5056(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-649; SER-688; SER-689
RP   AND SER-701, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-649; SER-688 AND
RP   SER-689, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 UL12.
RX   PubMed=20943970; DOI=10.1128/JVI.01506-10;
RA   Balasubramanian N., Bai P., Buchek G., Korza G., Weller S.K.;
RT   "Physical interaction between the herpes simplex virus type 1
RT   exonuclease, UL12, and the DNA double-strand break-sensing MRN
RT   complex.";
RL   J. Virol. 84:12504-12514(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688 AND SER-689, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688 AND SER-689, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   INVOLVEMENT IN NPHP-RC.
RX   PubMed=22863007; DOI=10.1016/j.cell.2012.06.028;
RA   Chaki M., Airik R., Ghosh A.K., Giles R.H., Chen R., Slaats G.G.,
RA   Wang H., Hurd T.W., Zhou W., Cluckey A., Gee H.Y., Ramaswami G.,
RA   Hong C.J., Hamilton B.A., Cervenka I., Ganji R.S., Bryja V.,
RA   Arts H.H., van Reeuwijk J., Oud M.M., Letteboer S.J., Roepman R.,
RA   Husson H., Ibraghimov-Beskrovnaya O., Yasunaga T., Walz G., Eley L.,
RA   Sayer J.A., Schermer B., Liebau M.C., Benzing T., Le Corre S.,
RA   Drummond I., Janssen S., Allen S.J., Natarajan S., O'Toole J.F.,
RA   Attanasio M., Saunier S., Antignac C., Koenekoop R.K., Ren H.,
RA   Lopez I., Nayir A., Stoetzel C., Dollfus H., Massoudi R.,
RA   Gleeson J.G., Andreoli S.P., Doherty D.G., Lindstrad A., Golzio C.,
RA   Katsanis N., Pape L., Abboud E.B., Al-Rajhi A.A., Lewis R.A.,
RA   Omran H., Lee E.Y., Wang S., Sekiguchi J.M., Saunders R.,
RA   Johnson C.A., Garner E., Vanselow K., Andersen J.S., Shlomai J.,
RA   Nurnberg G., Nurnberg P., Levy S., Smogorzewska A., Otto E.A.,
RA   Hildebrandt F.;
RT   "Exome capture reveals ZNF423 and CEP164 mutations, linking renal
RT   ciliopathies to DNA damage response signaling.";
RL   Cell 150:533-548(2012).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-649; SER-688 AND
RP   SER-689, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   VARIANT ATLD1 SER-117.
RX   PubMed=10612394; DOI=10.1016/S0092-8674(00)81547-0;
RA   Stewart G.S., Maser R.S., Stankovic T., Bressan D.A., Kaplan M.I.,
RA   Jaspers N.G.J., Raams A., Byrd P.J., Petrini J.H.J., Taylor A.M.R.;
RT   "The DNA double-strand break repair gene hMRE11 is mutated in
RT   individuals with an ataxia-telangiectasia-like disorder.";
RL   Cell 99:577-587(1999).
RN   [27]
RP   VARIANTS CANCER CYS-104; HIS-503 AND GLN-572.
RX   PubMed=11196167;
RA   Fukuda T., Sumiyoshi T., Takahashi M., Kataoka T., Asahara T.,
RA   Inui H., Watatani M., Yasutomi M., Kamada N., Miyagawa K.;
RT   "Alterations of the double-strand break repair gene MRE11 in cancer.";
RL   Cancer Res. 61:23-26(2001).
RN   [28]
RP   VARIANT OVARIAN CANCER TRP-305.
RX   PubMed=14684699; DOI=10.1136/jmg.40.12.e131;
RA   Heikkinen K., Karppinen S.-M., Soini Y., Maekinen M., Winqvist R.;
RT   "Mutation screening of Mre11 complex genes: indication of RAD50
RT   involvement in breast and ovarian cancer susceptibility.";
RL   J. Med. Genet. 40:E131-E131(2003).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-237 AND TYR-302.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Component of the MRN complex, which plays a central role
CC       in double-strand break (DSB) repair, DNA recombination,
CC       maintenance of telomere integrity and meiosis. The complex
CC       possesses single-strand endonuclease activity and double-strand-
CC       specific 3'-5' exonuclease activity, which are provided by MRE11A.
CC       RAD50 may be required to bind DNA ends and hold them in close
CC       proximity. This could facilitate searches for short or long
CC       regions of sequence homology in the recombining DNA templates, and
CC       may also stimulate the activity of DNA ligases and/or restrict the
CC       nuclease activity of MRE11A to prevent nucleolytic degradation
CC       past a given point. The complex may also be required for DNA
CC       damage signaling via activation of the ATM kinase. In telomeres
CC       the MRN complex may modulate t-loop formation.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- SUBUNIT: Component of the MRN complex composed of two heterodimers
CC       RAD50/MRE11A associated with a single NBN. Component of the BASC
CC       complex, at least composed of BRCA1, MSH2, MSH6, MLH1, ATM, BLM,
CC       RAD50, MRE11A and NBN (By similarity). Interacts with
CC       DCLRE1C/Artemis and DCLRE1B/Apollo. Interacts with ATF2. Interacts
CC       with herpes simplex virus 1 protein UL12 (PubMed:20943970).
CC       {ECO:0000250, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15723659, ECO:0000269|PubMed:15916964,
CC       ECO:0000269|PubMed:18469862, ECO:0000269|PubMed:20943970}.
CC   -!- INTERACTION:
CC       Q9BXW9:FANCD2; NbExp=6; IntAct=EBI-396513, EBI-359343;
CC       P16104:H2AFX; NbExp=6; IntAct=EBI-396513, EBI-494830;
CC       P42858:HTT; NbExp=5; IntAct=EBI-396513, EBI-466029;
CC       O60934:NBN; NbExp=2; IntAct=EBI-396513, EBI-494844;
CC       O75943:RAD17; NbExp=2; IntAct=EBI-396513, EBI-968231;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Note=Localizes to
CC       discrete nuclear foci after treatment with genotoxic agents.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P49959-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49959-2; Sequence=VSP_003262;
CC       Name=3;
CC         IsoId=P49959-3; Sequence=VSP_057350;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Ataxia-telangiectasia-like disorder 1 (ATLD1)
CC       [MIM:604391]: A rare disorder characterized by progressive
CC       cerebellar ataxia, dysarthria, abnormal eye movements, and absence
CC       of telangiectasia. ATLD patients show normal levels of total IgG,
CC       IgA and IgM, although there may be reduced levels of specific
CC       functional antibodies. At the cellular level, ATLD exhibits
CC       hypersensitivity to ionizing radiation and radioresistant DNA
CC       synthesis. {ECO:0000269|PubMed:10612394}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in MRE11A can be a cause of
CC       nephronophthisis-related ciliopathies (NPHP-RC), a group of
CC       recessive diseases that affect kidney, retina and brain. A
CC       homozygous truncating mutation MRE11A has been found in patients
CC       with cerebellar vermis hypoplasia, ataxia and dysarthria.
CC   -!- MISCELLANEOUS: In case of infection by adenovirus E4, the MRN
CC       complex is inactivated and degraded by viral oncoproteins, thereby
CC       preventing concatenation of viral genomes in infected cells.
CC   -!- SIMILARITY: Belongs to the MRE11/RAD32 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MRE11ID247.html";
CC   -!- WEB RESOURCE: Name=MRE11base; Note=MRE11A mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/MRE11Abase/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mre11a/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37359; AAC78721.1; -; mRNA.
DR   EMBL; AF022778; AAD10197.1; -; mRNA.
DR   EMBL; AF073362; AAC36249.1; -; mRNA.
DR   EMBL; AF303395; AAK18790.1; -; Genomic_DNA.
DR   EMBL; AF303379; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303380; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303381; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303382; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303383; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303384; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303385; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303386; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303387; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303388; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303389; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303390; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303391; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303392; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303393; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AF303394; AAK18790.1; JOINED; Genomic_DNA.
DR   EMBL; AK095388; BAG53039.1; -; mRNA.
DR   EMBL; AY584241; AAS79320.1; -; Genomic_DNA.
DR   EMBL; AP000765; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000786; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF455448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC063458; AAH63458.1; -; mRNA.
DR   CCDS; CCDS8298.1; -. [P49959-2]
DR   CCDS; CCDS8299.1; -. [P49959-1]
DR   RefSeq; NP_005581.2; NM_005590.3. [P49959-2]
DR   RefSeq; NP_005582.1; NM_005591.3. [P49959-1]
DR   RefSeq; XP_011541139.1; XM_011542837.1. [P49959-1]
DR   UniGene; Hs.192649; -.
DR   PDB; 3T1I; X-ray; 3.00 A; A/B/C/D=1-411.
DR   PDBsum; 3T1I; -.
DR   ProteinModelPortal; P49959; -.
DR   SMR; P49959; 8-400.
DR   BioGrid; 110501; 81.
DR   DIP; DIP-33238N; -.
DR   IntAct; P49959; 22.
DR   MINT; MINT-131851; -.
DR   STRING; 9606.ENSP00000325863; -.
DR   PhosphoSite; P49959; -.
DR   BioMuta; MRE11A; -.
DR   DMDM; 17380137; -.
DR   MaxQB; P49959; -.
DR   PaxDb; P49959; -.
DR   PRIDE; P49959; -.
DR   DNASU; 4361; -.
DR   Ensembl; ENST00000323929; ENSP00000325863; ENSG00000020922.
DR   Ensembl; ENST00000323977; ENSP00000326094; ENSG00000020922. [P49959-2]
DR   Ensembl; ENST00000407439; ENSP00000385614; ENSG00000020922. [P49959-3]
DR   GeneID; 4361; -.
DR   KEGG; hsa:4361; -.
DR   UCSC; uc001peu.2; human. [P49959-1]
DR   UCSC; uc001pev.2; human. [P49959-2]
DR   UCSC; uc009ywj.2; human.
DR   CTD; 4361; -.
DR   GeneCards; GC11M094150; -.
DR   HGNC; HGNC:7230; MRE11A.
DR   HPA; CAB004081; -.
DR   HPA; HPA002691; -.
DR   MIM; 600814; gene.
DR   MIM; 604391; phenotype.
DR   neXtProt; NX_P49959; -.
DR   Orphanet; 251347; Ataxia-telangiectasia-like disorder.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   PharmGKB; PA30934; -.
DR   eggNOG; COG0420; -.
DR   GeneTree; ENSGT00390000017288; -.
DR   HOGENOM; HOG000216581; -.
DR   HOVERGEN; HBG052508; -.
DR   InParanoid; P49959; -.
DR   KO; K10865; -.
DR   OMA; RMFVNKQ; -.
DR   OrthoDB; EOG7VB2F1; -.
DR   PhylomeDB; P49959; -.
DR   TreeFam; TF101105; -.
DR   Reactome; REACT_118823; Cytosolic sensors of pathogen-associated DNA.
DR   Reactome; REACT_163993; IRF3-mediated induction of type I IFN.
DR   Reactome; REACT_169185; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; REACT_27271; Meiotic recombination.
DR   Reactome; REACT_486; Assembly of the RAD50-MRE11-NBS1 complex at DNA double-strand breaks.
DR   ChiTaRS; MRE11A; human.
DR   GeneWiki; MRE11A; -.
DR   GenomeRNAi; 4361; -.
DR   NextBio; 17163; -.
DR   PMAP-CutDB; P49959; -.
DR   PRO; PR:P49959; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P49959; -.
DR   CleanEx; HS_MRE11A; -.
DR   ExpressionAtlas; P49959; baseline and differential.
DR   Genevisible; P49959; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0000794; C:condensed nuclear chromosome; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030870; C:Mre11 complex; NAS:BHF-UCL.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IDA:CACAO.
DR   GO; GO:0003690; F:double-stranded DNA binding; TAS:ProtInc.
DR   GO; GO:0004520; F:endodeoxyribonuclease activity; IDA:CACAO.
DR   GO; GO:0030145; F:manganese ion binding; IEA:InterPro.
DR   GO; GO:0004518; F:nuclease activity; TAS:BHF-UCL.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0000014; F:single-stranded DNA endodeoxyribonuclease activity; IDA:CACAO.
DR   GO; GO:0006284; P:base-excision repair; IBA:GO_Central.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:MGI.
DR   GO; GO:0032508; P:DNA duplex unwinding; IMP:BHF-UCL.
DR   GO; GO:0006310; P:DNA recombination; TAS:ProtInc.
DR   GO; GO:0006281; P:DNA repair; TAS:Reactome.
DR   GO; GO:0006302; P:double-strand break repair; TAS:Reactome.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:Reactome.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IDA:CACAO.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0031573; P:intra-S DNA damage checkpoint; IBA:GO_Central.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0032876; P:negative regulation of DNA endoreduplication; IMP:BHF-UCL.
DR   GO; GO:0046597; P:negative regulation of viral entry into host cell; IEA:Ensembl.
DR   GO; GO:0090305; P:nucleic acid phosphodiester bond hydrolysis; IDA:GOC.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IDA:BHF-UCL.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0000019; P:regulation of mitotic recombination; TAS:ProtInc.
DR   GO; GO:0007062; P:sister chromatid cohesion; IMP:BHF-UCL.
DR   GO; GO:0007129; P:synapsis; IEA:Ensembl.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; TAS:ProtInc.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.60.21.10; -; 2.
DR   InterPro; IPR004843; Calcineurin-like_PHP_apaH.
DR   InterPro; IPR003701; DNA_repair_Mre11.
DR   InterPro; IPR029052; Metallo-depent_PP-like.
DR   InterPro; IPR007281; Mre11_DNA-bd.
DR   PANTHER; PTHR10139; PTHR10139; 1.
DR   Pfam; PF00149; Metallophos; 1.
DR   Pfam; PF04152; Mre11_DNA_bind; 1.
DR   PIRSF; PIRSF000882; DSB_repair_MRE11; 1.
DR   SUPFAM; SSF56300; SSF56300; 2.
DR   TIGRFAMs; TIGR00583; mre11; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Ciliopathy;
KW   Complete proteome; Disease mutation; DNA damage; DNA repair;
KW   Endonuclease; Exonuclease; Host-virus interaction; Hydrolase;
KW   Manganese; Meiosis; Nuclease; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895}.
FT   CHAIN         2    708       Double-strand break repair protein
FT                                MRE11A.
FT                                /FTId=PRO_0000138672.
FT   ACT_SITE    129    129       Proton donor. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000269|PubMed:19413330,
FT                                ECO:0000269|PubMed:22223895}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61216}.
FT   MOD_RES     649    649       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     688    688       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     689    689       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     701    701       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   VAR_SEQ       1      7       MSTADAL -> MNRNISHQKG (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057350.
FT   VAR_SEQ     595    622       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8530104}.
FT                                /FTId=VSP_003262.
FT   VARIANT     104    104       S -> C (in cancer).
FT                                {ECO:0000269|PubMed:11196167}.
FT                                /FTId=VAR_011625.
FT   VARIANT     117    117       N -> S (in ATLD1).
FT                                {ECO:0000269|PubMed:10612394}.
FT                                /FTId=VAR_008513.
FT   VARIANT     157    157       M -> V (in dbSNP:rs147771140).
FT                                /FTId=VAR_011626.
FT   VARIANT     237    237       F -> C (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036416.
FT   VARIANT     302    302       H -> Y (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036417.
FT   VARIANT     305    305       R -> W (in ovarian cancer).
FT                                {ECO:0000269|PubMed:14684699}.
FT                                /FTId=VAR_025528.
FT   VARIANT     468    468       D -> G (in dbSNP:rs1805367).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019288.
FT   VARIANT     503    503       R -> H (in cancer).
FT                                {ECO:0000269|PubMed:11196167}.
FT                                /FTId=VAR_011627.
FT   VARIANT     572    572       R -> Q (in cancer; dbSNP:rs200085146).
FT                                {ECO:0000269|PubMed:11196167}.
FT                                /FTId=VAR_011628.
FT   VARIANT     698    698       M -> V (in dbSNP:rs1805362).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_019289.
FT   CONFLICT     31     31       V -> A (in Ref. 1; AAC78721).
FT                                {ECO:0000305}.
FT   HELIX         9     11       {ECO:0000244|PDB:3T1I}.
FT   STRAND       12     18       {ECO:0000244|PDB:3T1I}.
FT   TURN         24     26       {ECO:0000244|PDB:3T1I}.
FT   TURN         30     34       {ECO:0000244|PDB:3T1I}.
FT   HELIX        35     49       {ECO:0000244|PDB:3T1I}.
FT   STRAND       53     57       {ECO:0000244|PDB:3T1I}.
FT   STRAND       62     66       {ECO:0000244|PDB:3T1I}.
FT   HELIX        69     83       {ECO:0000244|PDB:3T1I}.
FT   STRAND      122    124       {ECO:0000244|PDB:3T1I}.
FT   STRAND      128    130       {ECO:0000244|PDB:3T1I}.
FT   TURN        134    137       {ECO:0000244|PDB:3T1I}.
FT   HELIX       140    147       {ECO:0000244|PDB:3T1I}.
FT   STRAND      149    152       {ECO:0000244|PDB:3T1I}.
FT   STRAND      162    164       {ECO:0000244|PDB:3T1I}.
FT   STRAND      167    171       {ECO:0000244|PDB:3T1I}.
FT   STRAND      174    181       {ECO:0000244|PDB:3T1I}.
FT   HELIX       186    194       {ECO:0000244|PDB:3T1I}.
FT   STRAND      198    200       {ECO:0000244|PDB:3T1I}.
FT   HELIX       207    209       {ECO:0000244|PDB:3T1I}.
FT   STRAND      210    216       {ECO:0000244|PDB:3T1I}.
FT   STRAND      223    228       {ECO:0000244|PDB:3T1I}.
FT   HELIX       231    233       {ECO:0000244|PDB:3T1I}.
FT   STRAND      240    243       {ECO:0000244|PDB:3T1I}.
FT   STRAND      250    255       {ECO:0000244|PDB:3T1I}.
FT   TURN        257    259       {ECO:0000244|PDB:3T1I}.
FT   STRAND      262    265       {ECO:0000244|PDB:3T1I}.
FT   HELIX       276    279       {ECO:0000244|PDB:3T1I}.
FT   STRAND      283    290       {ECO:0000244|PDB:3T1I}.
FT   STRAND      293    300       {ECO:0000244|PDB:3T1I}.
FT   STRAND      302    304       {ECO:0000244|PDB:3T1I}.
FT   STRAND      307    313       {ECO:0000244|PDB:3T1I}.
FT   HELIX       314    316       {ECO:0000244|PDB:3T1I}.
FT   TURN        318    320       {ECO:0000244|PDB:3T1I}.
FT   HELIX       328    350       {ECO:0000244|PDB:3T1I}.
FT   TURN        351    353       {ECO:0000244|PDB:3T1I}.
FT   STRAND      355    357       {ECO:0000244|PDB:3T1I}.
FT   STRAND      362    368       {ECO:0000244|PDB:3T1I}.
FT   TURN        370    372       {ECO:0000244|PDB:3T1I}.
FT   HELIX       379    385       {ECO:0000244|PDB:3T1I}.
FT   TURN        386    388       {ECO:0000244|PDB:3T1I}.
FT   STRAND      392    399       {ECO:0000244|PDB:3T1I}.
SQ   SEQUENCE   708 AA;  80593 MW;  D94ABFBDDF6106AD CRC64;
     MSTADALDDE NTFKILVATD IHLGFMEKDA VRGNDTFVTL DEILRLAQEN EVDFILLGGD
     LFHENKPSRK TLHTCLELLR KYCMGDRPVQ FEILSDQSVN FGFSKFPWVN YQDGNLNISI
     PVFSIHGNHD DPTGADALCA LDILSCAGFV NHFGRSMSVE KIDISPVLLQ KGSTKIALYG
     LGSIPDERLY RMFVNKKVTM LRPKEDENSW FNLFVIHQNR SKHGSTNFIP EQFLDDFIDL
     VIWGHEHECK IAPTKNEQQL FYISQPGSSV VTSLSPGEAV KKHVGLLRIK GRKMNMHKIP
     LHTVRQFFME DIVLANHPDI FNPDNPKVTQ AIQSFCLEKI EEMLENAERE RLGNSHQPEK
     PLVRLRVDYS GGFEPFSVLR FSQKFVDRVA NPKDIIHFFR HREQKEKTGE EINFGKLITK
     PSEGTTLRVE DLVKQYFQTA EKNVQLSLLT ERGMGEAVQE FVDKEEKDAI EELVKYQLEK
     TQRFLKERHI DALEDKIDEE VRRFRETRQK NTNEEDDEVR EAMTRARALR SQSEESASAF
     SADDLMSIDL AEQMANDSDD SISAATNKGR GRGRGRRGGR GQNSASRGGS QRGRADTGLE
     TSTRSRNSKT AVSASRNMSI IDAFKSTRQQ PSRNVTTKNY SEVIEVDESD VEEDIFPTTS
     KTDQRWSSTS SSKIMSQSQV SKGVDFESSE DDDDDPFMNT SSLRRNRR
//
